# Biobank Equipment Market

> Biobank Equipment Market Research Report By Product Type (Freezers, Incubators, Automated Storage Systems, Sample Processing Systems, Refrigerators), By Application (Clinical Diagnostics, Research and Development, Genetic Research, Pharmaceuticals, Biotechnology), By End Use (Hospitals, Research Institutions, Pharmaceutical Companies, Biotechnology Firms), By Ownership Type (Private, Public, Non-profit) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2026 To 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 4.35%
- **2025:** USD 40.10 Billion
- **2035:** USD 61.25 Billion
- **Key Players:** Thermo Fisher Scientific, PHC Holdings Corporation, Haier Biomedical, Azenta Life Sciences, Eppendorf SE, Merck KGaA, Cryoport (MVE Biological Solutions), Avantor

**Report ID:** MRFR/HC/40626-HCR · **Pages:** 200 · **Author:** Satyendra Maurya & Kinjoll Dey · **Last Updated:** November 03, 2026

**URL:** https://www.marketresearchfuture.com/reports/biobank-equipment-market-42291

---

## Market Summary

## Biobank Equipment Market Summary

The biobank equipment market was valued at USD 40.10 Billion in 2025 and is projected to reach USD 41.75 Billion in 2026, rising to USD 61.25 Billion by 2035 at a CAGR of 4.35% over 2026–2035. Two kinds of programs are behind most of this growth: population-scale cohorts and large proteomics initiatives. The US All of Us Research Program aims to enroll at least one million participants and keeps their biospecimens in a central repository [1]. The UK Biobank Pharma Proteomics Project is profiling 600,000 samples [2]. Both convert research ambition into multi-year orders for freezers, automated stores and monitoring hardware.

Storage technology is changing quickly. Older cascade-compressor freezers running on high-GWP HFC blends, manual liquid-nitrogen dewars and paper temperature logs are being replaced by variable-speed hydrocarbon freezers, automated −80 °C and −150 °C stores, and cloud-connected alarm networks. US rules under the AIM Act phase down HFC production by 85% by 2036 [4], and ENERGY STAR criteria for laboratory-grade freezers now reward lower daily energy use [5]. Together, these accelerate replacement of the installed fleet.

North America holds a 38.5% share, supported by federal cohort funding and a dense base of cell and [gene therapy](https://www.marketresearchfuture.com/reports/gene-therapy-market-8399) developers. Asia-Pacific is the fastest-growing region at a 6.1% CAGR, driven by national genome programs in India, Japan, China and South Korea. Europe ranks second, and its procurement is shaped by Regulation (EU) 2024/1938 on substances of human origin [6]. Over the forecast period, purchasing will shift toward connected, validated and energy-efficient systems rather than toward more storage capacity alone.

## Key Report Takeaways

### • By Product

- Cryogenic Storage Systems account for 55.5% of the biobank equipment market in 2025, reflecting their central role in preserving advanced-therapy material.
- Freezers are the fastest-growing product line, expanding at a 5.8% CAGR through 2035.
- Alarm & Monitoring Systems grow at a 5.2% CAGR as operators retrofit compliance capability onto installed fleets.

### • By Application

- [Regenerative Medicine](https://www.marketresearchfuture.com/reports/regenerative-medicine-market-2220) leads applications with a 38.6% share in 2025.
- Life-Science & Genomic Research posts the highest application CAGR at 6.6%, supported by multi-omics programs.
- Drug Discovery generates USD 9.30 Billion in 2025 revenue.

### • By End User

- Biobanks & Biorepositories represent 47.0% of the biobank equipment market in 2025.
- Hospitals & Diagnostic Centres expand at a 5.3% CAGR as specimen banking moves closer to patients.
- Pharma & Biotech Companies account for USD 8.22 Billion in 2025.

### • By Region

- North America holds a 38.5% share in 2025.
- Europe generates USD 10.99 billion in 2025.
- Asia-Pacific is the fastest-growing region at a 6.1% CAGR.

## Market Size and Forecast (2026–2035)

Market Research Future sized the biobank equipment market bottom-up. Shipment volumes and installed-base data for refrigerators, freezers, ice machines and monitoring systems were multiplied by average selling prices that vary by region and end user. The totals were then checked against vendor annual reports [20][21][22][23], public cohort-program budgets [1][3] and interviews with repository managers. Historical values for 2021–2024 rest on reported vendor revenue. Forecasts assume the regulatory timelines in force at publication.

## Market Drivers

## Driver Impact Analysis

The impact percentages below show the direction and relative size of each driver's influence on the biobank equipment market CAGR. They are not additive: the drivers overlap, reinforce one another and are offset by the restraints in Section 5, so they should not be summed to reconstruct the headline growth rate.

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Population-scale cohort programs | +1.1% | North America, Europe, South Korea | Long-term (≥4 yr) | [1][3][25] |
| Cell and gene therapy commercialization | +0.9% | North America, Europe | Medium-term (2–4 yr) | [9] |
| Accreditation and storage compliance mandates | +0.6% | Europe, North America | Short-term (≤2 yr) | [6][7][11] |
| Energy-efficiency and refrigerant transition rules | +0.5% | North America, Europe | Short-term (≤2 yr) | [4][5][19] |
| Automated sample storage and retrieval | +0.6% | Global | Medium-term (2–4 yr) | [2][12] |
| Asia-Pacific national genome investment | +0.7% | Asia-Pacific | Long-term (≥4 yr) | [13][15] |
| Pharma proteomics and biomarker programs | +0.4% | Global | Medium-term (2–4 yr) | [20] |

### Population-Scale Cohort Programs

All of Us aims to enroll at least one million US participants and stores blood, urine and saliva in a central repository [1]. Our Future Health targets 5 million UK adults [3], and South Korea's bio big-data initiative plans for 1 million participants through the National Biobank of Korea [25]. A single participant can produce ten or more aliquots that must stay stable for decades, so each enrollment target becomes a long procurement queue for freezers, racks and monitoring.

### Cell and Gene Therapy Commercialization

The FDA's list of approved cellular and gene therapy products now exceeds 30 entries. Each autologous product needs chain-of-identity control and vapor-phase storage below −150 °C. Under 21 CFR Part 1271, establishments handling human cells and tissues must maintain storage conditions that prevent contamination and deterioration [9]. Developers and contract manufacturers therefore build satellite repositories next to manufacturing suites, which adds demand for [cryogenic freezers](https://www.marketresearchfuture.com/reports/cryogenic-freezers-market-11764) and backup capacity in clinical-trial regions.

### Accreditation and Storage Compliance Mandates

ISO 20387:2018 sets general requirements for biobank competence and is becoming a condition for research partnerships [7]. Regulation (EU) 2024/1938 extends quality and vigilance duties across all 27 member states from 2027 [6]. FDA 21 CFR Part 11 requires secure audit trails for electronic records [11]. These rules push repositories toward validated freezers with continuous logging, documented calibration and sample traceability, which turns compliance budgets into equipment upgrades.

### Energy-Efficiency and Refrigerant Transition Rules

The AIM Act requires an 85% phase-down of HFC production by 2036, and the 2023 Technology Transitions rule restricts high-GWP refrigerants in new equipment [4]. ENERGY STAR certification for laboratory-grade freezers sets measurable daily energy ceilings [5]. Freezer Challenge results show that raising setpoints from −80 °C to −70 °C can cut energy use by about 30% [19]. Sustainability offices increasingly approve replacements on energy payback grounds.

### Automated Sample Storage and Retrieval

Large retrieval programs need automation. The UK Biobank proteomics effort requires picking and shipping 600,000 samples [2], a volume that manual chest freezers cannot handle without repeated warming. NCI best practices advise minimizing freeze–thaw cycles to protect specimen integrity [12]. Automated −80 °C stores with barcode reading and robotic pickers solve both problems, and each system typically sells for several million dollars.

### Asia-Pacific National Genome Investment

India's Genome India Project completed and released data from 10,000 genomes in 2025, establishing a national reference repository. Japan's Tohoku Medical Megabank holds specimens from roughly 150,000 participants [15]. China's 2023 Human Genetic Resources implementation rules encourage keeping biological material inside the country [13], which pushes domestic storage build-out. These programs explain why Asia-Pacific grows faster than the global average.

### Pharma Proteomics and Biomarker Programs

Thermo Fisher Scientific's acquisition of Olink, valued at about USD 3.1 billion and completed in 2024, shows how central high-plex proteomics has become to pharmaceutical R&D [20]. Proteomic assays depend on well-characterized archived samples, so sponsors invest in −80 °C capacity, temperature mapping and retrieval automation. Biomarker-led trial designs prolong retention periods, which raises the installed storage base each sponsor must maintain.

## Restraints

## Restraints Impact Analysis

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| High capital and energy costs | −0.6% | Global, especially emerging markets | Medium-term (2–4 yr) | [19] |
| Liquid nitrogen supply and safety risk | −0.3% | Global | Short-term (≤2 yr) | [8] |
| Cross-border data and material restrictions | −0.4% | China, Europe | Long-term (≥4 yr) | [13][24] |
| Public research funding volatility | −0.3% | North America, Europe | Short-term (≤2 yr) | [1] |
| Skilled workforce and integration gaps | −0.2% | Global | Medium-term (2–4 yr) | [11] |

### High Capital and Energy Costs

A single −80 °C freezer can use as much electricity as an average US household, often 16–20 kWh per day [19]. Automated stores multiply that cost and also need dedicated rooms, backup power and service contracts. Academic and emerging-market repositories frequently postpone replacements, run aging units past their design life and buy only partial monitoring coverage, which slows unit volumes outside well-funded centers.

### Liquid Nitrogen Supply and Safety Risk

Vapor-phase storage relies on steady bulk nitrogen deliveries, and regional gas shortages or surcharges directly raise operating costs. ISBER best practices call for oxygen-depletion monitoring because displaced oxygen below about 19.5% creates an asphyxiation hazard [8]. Safety retrofits, ventilation and training increase installation costs, and some hospitals choose not to host cryogenic storage on site.

### Cross-Border Data and Material Restrictions

China's Human Genetic Resources rules require approval before foreign parties can access or export samples [13]. GDPR penalties can reach 4% of global annual turnover [24]. Multinational sponsors respond by fragmenting storage into national silos, which raises equipment needs but complicates central procurement, delays tenders and reduces the economies of scale vendors depend on.

### Public Research Funding Volatility

Cohort programs depend on annual appropriations. The All of Us program reported reduced fiscal 2024 funding that slowed some enrollment and engagement activity [1]. Budget uncertainty leads repositories to delay automation purchases and stretch service intervals, which creates uneven quarterly demand for vendors that depend on government-funded academic customers.

### Skilled Workforce and Integration Gaps

Validated systems need staff who understand cryogenic handling, IQ/OQ/PQ protocols and Part 11 electronic-record controls [11]. Many sites lack biobank informatics specialists, so connecting freezers to inventory software takes months. Integration delays push out acceptance milestones and payments, and smaller buyers often choose basic standalone units over connected platforms.

## Opportunities

## Biobank Equipment Market Opportunities

### Emerging-Market National Biobanks

Gulf and South American genome programs have a definite geographic deficit for vendors. The Saudi Genome Program has sequenced tens of thousands of its residents to promote precision medicine, and Qatar Biobank maintains a national population cohort. Brazil’s Genomas Brasil program has set a target of 100,000 genomes [18]. Where local integrators are few, vendors offering complete packages of freezers, LN2 infrastructure, monitoring and training can win tenders.

### Storage-as-a-Service and Data Monetization

Vendors are transitioning from one-off hardware sales to recurrent revenue, such as managed-storage contracts, pay-per-pick retrieval and subscription monitoring dashboards. Thousands of connected machines can sell anonymized performance data back to clients as predictive-maintenance and benchmarking intelligence. Azenta’s sample-management services demonstrate that storage operations may deliver annuity income beyond equipment sales [21].

### Retrofit Monitoring for the Installed Base

A lot of the freezer fleet around the world still operates without networked alarms. Older units can be brought into conformity with wireless probes, gateways and Part 11 compliant software at a fraction of the cost of replacement [11]. That’s why Alarm & Monitoring Systems are expanding at 5.2%, and why vendors with brand-neutral monitoring platforms may attract customers who bought refrigerators from competitors.

### Natural-Refrigerant and LN2-Free Freezers

The HFC phase-down [4] and ENERGY STAR requirements [5] support freezers charged with hydrocarbons and mechanical −150 °C systems without nitrogen. Laboratories already tracking energy savings per unit [19] are participating in the Freezer Challenge. Institutional sustainability offices write criteria that can be captured by suppliers, confirmed for kWh-per-day statistics and lifecycle carbon numbers.

### Decentralized Hospital Storage Nodes

Hospital collection locations pre-process and store specimens before transferring them to national repositories. This creates a need for compact, plug-and-play freezers and remote surveillance. This hub-and-spoke strategy is the genesis of the 5.3% CAGR of Hospitals & Diagnostic Centers. Integrated delivery networks are particularly suited to standardized modules that can be duplicated in dozens of sites.

## Future Outlook

## Biobank Equipment Market Future Outlook

### AI-Enabled Predictive Monitoring

Monitoring will shift from threshold alarms to prediction. Compressor current, door-opening frequency and warm-up curves from connected freezers give machine-learning models enough data to flag failures days ahead. Part 11-compliant platforms [11] that combine these predictions with automated service dispatch will become the standard, and vendors will compete on how many sample-loss events they prevent rather than on hardware specifications alone.

### Platform Economics of Automated Stores

Automated −80 °C and −150 °C stores are becoming platforms. Hardware sales, software licenses, consumables such as barcoded tubes and racks, and retrieval services together lock customers in for ten years or more. Large retrieval programs such as UK Biobank's proteomics effort [2] show that throughput, not capacity, now limits value, which favors vendors that can upgrade pick rates in place.

### Sustainability and ESG Reporting

Institutional carbon reporting will make freezer energy use a board-level metric. The AIM Act phase-down [4] and the Freezer Challenge's documented setpoint savings [19] give procurement teams numbers to cite. Vendors will need to publish verified lifecycle emissions, offer take-back of retired units, and support −70 °C operating protocols to stay on approved supplier lists.

### Decentralized Advanced-Therapy Storage

Point-of-care cell therapy manufacturing and hospital storage nodes will spread cryogenic capacity across many smaller sites. Integrated cold chain management, linking collection, processing, storage and shipment under one chain of identity, will matter more as FDA-approved therapies multiply. Equipment designed for distributed fleets, with central oversight, will take share from standalone units.

## Segment Insights

## Biobank Equipment Market Segmentation

### By Product

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Cryogenic Storage Systems | 55.5% share | Advanced-therapy preservation and cohort archiving |
| — Refrigerators | USD 5.62 Billion | Short-cycle sample preparation and reagent storage |
| — Freezers | 5.8% CAGR | Satellite repositories near manufacturing suites |
| — Ice Machines | 2.9% share | Sample transport and bench-side processing |
| Alarm & Monitoring Systems | 5.2% CAGR | Retrofit compliance on installed fleets |

Within the biobank equipment market, Cryogenic Storage Systems lead because every repository's core asset is the stability of its temperature-controlled inventory. Freezers grow fastest within the category, driven by cell therapy developers and contract manufacturers that add vapor-phase and −80 °C capacity next to production. Refrigerators remain essential for short-term workflows, and Ice Machines serve a niche transport role. Alarm & Monitoring Systems grow quickly as operators add networked oversight to older units [11].

### By Application

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Regenerative Medicine | 38.6% share | Commercial stem-cell and gene-edited therapies |
| Drug Discovery | USD 9.30 Billion | High-throughput screening on characterized bioarchives |
| Disease & Epidemiology Research | 20.9% share | Population cohorts and disease surveillance |
| Life-Science & Genomic Research | 6.6% CAGR | Multi-omics and proteomics programs |

Application demand in the biobank equipment market is led by Regenerative Medicine, where GMP-grade storage below −150 °C is mandatory for living cell products [9]. Life-Science & Genomic Research grows fastest because multi-omics studies keep nucleic acids, proteins and metabolites side by side and need rapid, low-warm-up retrieval [2]. Drug Discovery provides steady revenue from screening libraries, and Disease & Epidemiology Research scales with national cohort enrollment [1].

### By End User

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Biobanks & Biorepositories | 47.0% share | Long-term archiving and national cohort storage |
| Pharma & Biotech Companies | USD 8.22 Billion | Clinical-trial sample retention and outsourcing |
| Academic & Research Institutes | 19.1% share | Early adoption of automated storage |
| Hospitals & Diagnostic Centres | 5.3% CAGR | Near-patient specimen banking |

End-user spending in the biobank equipment market is concentrated in Biobanks & Biorepositories, which increasingly act as long-term archives and overflow facilities for distributed collection networks. Hospitals & Diagnostic Centres grow fastest as hub-and-spoke models place compact freezers at collection sites. Pharma & Biotech Companies outsource more storage but still fund trial-specific capacity, while Academic & Research Institutes continue to pilot automation ahead of broader adoption [12].

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Key Metric (2025) | Primary Investment Themes |
| --- | --- | --- |
| North America | 38.5% share | Federal cohorts, cell and gene therapy manufacturing, refrigerant transition |
| Europe | USD 10.99 Billion | SoHO compliance, ISO 20387 accreditation, energy efficiency |
| Asia-Pacific | 6.1% CAGR | National genome programs, domestic sample retention |
| South America | 5.9% share | Genomic sequencing programs, public hospital networks |
| Middle East & Africa | USD 1.84 Billion | Gulf genome programs, new national repositories |
| Total | USD 40.10 Billion | — |

Regional demand in the biobank equipment market follows the location of research funding, advanced-therapy manufacturing and national genome programs. North America leads on installed value, Europe on regulatory-driven upgrades and Asia-Pacific on new capacity.

### North America

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| United States | 86.4% of region | All of Us cohort and cell therapy manufacturing |
| Canada | 4.9% CAGR | Provincial biobank and genomics funding |
| Mexico | USD 0.62 Billion | Expansion of private hospitals and diagnostic laboratories |

The United States sets the region's pace. Federal cohort funding [1], FDA-regulated cell therapy manufacturing [9] and the HFC transition timetable [4] all point toward replacing and expanding the freezer fleet. Canadian provincial genomics agencies fund shared repositories that buy automated stores collectively. Mexico's demand comes mainly from private diagnostic chains and clinical-trial sites that need validated storage to qualify for multinational studies.

### Europe

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| Germany | 24.8% of region | University hospital biobank networks and pharma R&D |
| United Kingdom | USD 2.36 Billion | UK Biobank and Our Future Health |
| France | 4.4% CAGR | National cohort and oncology biobanks |
| Italy | 11.2% of region | Regional hospital research institutes |
| Spain | USD 0.86 Billion | National biobank platform and cell therapy trials |
| Rest of Europe | 4.0% CAGR | Nordic and Benelux registry-linked biobanks |

European procurement is driven by compliance. Regulation (EU) 2024/1938 harmonizes storage, traceability and vigilance requirements from 2027 [6], while ISO 20387 accreditation increasingly determines access to research consortia [7]. The United Kingdom stands out for scale: UK Biobank's proteomics retrieval [2] and Our Future Health's 5 million-participant target [3] need automated high-throughput storage. Germany's university hospital networks buy through centralized tenders that favor vendors offering validated documentation in German.

### Asia-Pacific

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| China | 37.5% of region | Domestic retention under HGR rules |
| Japan | USD 2.14 Billion | Tohoku Medical Megabank and regenerative medicine law |
| India | 8.4% CAGR | Genome India Project scale-up |
| Australia | 7.2% of region | Genomics health funding and clinical trials |
| South Korea | USD 0.81 Billion | National Project of Bio Big Data |
| Rest of Asia-Pacific | 6.0% CAGR | Singapore and Southeast Asian precision-medicine programs |

China's Human Genetic Resources rules [13] keep samples in the country, which favors domestic freezer manufacturers and adds repository capacity at provincial hospitals. India grows fastest from a small base as the Genome India Project moves from 10,000 genomes toward larger cohorts. Japan combines mature cohort infrastructure [15] with a regulatory framework that speeds regenerative-medicine products, sustaining demand for cryogenic storage. South Korea's million-participant initiative [25] supports multi-year orders for automated stores.

### South America

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| Brazil | 54.6% of region | Genomas Brasil program |
| Argentina | 4.8% CAGR | Public research institutes and oncology biobanks |
| Rest of South America | USD 0.62 Billion | Chile and Colombia clinical research capacity |

Brazil anchors regional demand through Genomas Brasil, which targets 100,000 genomes and funds sequencing and storage at partner institutions [18]. Currency swings and import duties raise landed equipment costs, so local service partnerships and refurbished units remain common. Argentina's public research institutes buy steadily when budgets allow, and multinational clinical-trial activity in Chile and Colombia drives demand for validated −80 °C capacity.

### Middle East & Africa

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| GCC | 5.6% CAGR | Saudi and Qatari national genome programs |
| South Africa | USD 0.41 Billion | Infectious disease and genomics research biobanks |
| Rest of Middle East & Africa | 37.0% of region | Donor-funded disease surveillance repositories |

GCC governments are funding greenfield repositories through the Saudi Genome Program and Qatar Biobank, usually as turnkey projects that bundle freezers, LN2 plants and monitoring. South Africa has the continent's deepest research-biobank base, tied to HIV and tuberculosis studies. Across the rest of Africa, donor-funded surveillance programs buy rugged, solar-compatible units that tolerate unstable power.

## Competitive Benchmarking

## Competitive Benchmarking

The biobank equipment market is moderately concentrated, with an estimated Herfindahl-Hirschman Index of 1,150–1,300 and an estimated combined share of 45–50% for the top five vendors. Broad-line laboratory suppliers dominate freezers and refrigerators. Specialists compete in automated stores, cryogenic logistics and monitoring software, and regional manufacturers in China gain share through domestic tenders [13]. Competition increasingly turns on service coverage, validation documentation and software integration rather than on price per cubic foot.

| Company | Est. Revenue Share Range | Key Offerings for biobank equipment market | Strategic Positioning |
| --- | --- | --- | --- |
| Thermo Fisher Scientific | ~14–18% | ULT freezers, LN2 storage, monitoring software | Broadest portfolio with global service reach |
| PHC Holdings Corporation | ~8–11% | VIP ECO series −80 °C freezers, incubators | Energy-efficient freezer leader |
| Haier Biomedical | ~6–9% | Cryogenic freezers, IoT-connected storage | Cost-competitive scale in Asia-Pacific |
| Azenta Life Sciences | ~5–8% | Automated −80 °C/−150 °C stores, sample services | Automation plus managed storage |
| Eppendorf SE | ~5–7% | CryoCube freezers, sample-handling consumables | Laboratory workflow integration |
| Merck KGaA | ~4–6% | Cryovials, storage consumables, lab equipment | Consumables-led ecosystem |
| Hamilton Company | ~3–5% | Automated sample stores, liquid handling | High-throughput automation specialist |
| Cryoport (MVE Biological Solutions) | ~3–5% | Vacuum-insulated LN2 freezers, dewars | Cell and gene therapy cold-chain focus |
| Avantor | ~2–4% | Laboratory freezers, consumables distribution | Channel and procurement breadth |
| Liconic AG | ~1–3% | Automated −80 °C and −20 °C stores | Modular automation for mid-size repositories |

## Recent News & Developments

## Recent News & Developments

- US EPA (October 2023): Finalized the Technology Transitions rule restricting high-GWP HFCs in new refrigeration equipment, accelerating freezer redesigns around hydrocarbon refrigerants [4].
- Ministry of Science and Technology, China (July 2023): Implementation rules on Human Genetic Resources took effect, tightening approval for foreign access and reinforcing domestic storage build-out [13].
- ISBER (2023): Published the fifth edition of its Best Practices, updating guidance on storage temperature monitoring, backup capacity and LN2 safety [8].
- European Union (July 2024): Regulation (EU) 2024/1938 on substances of human origin was published, setting harmonized storage and vigilance duties from 2027 [6].
- Thermo Fisher Scientific (July 2024): Completed its acquisition of Olink, expanding proteomics capacity that relies on archived sample retrieval [20].
- Department of Biotechnology, India (January 2025): Released data from 10,000 genomes under the Genome India Project, laying groundwork for larger national repositories.
- UK Biobank (January 2025): Launched a proteomics initiative covering 600,000 samples, one of the largest sample-retrieval programs ever undertaken [2].

## Report Scope

| Parameter | Details |
| --- | --- |
| Market Scope | The biobank equipment market covers cryogenic storage systems and alarm and monitoring systems sold through direct and distributor channels to biobanks, pharma and biotech companies, research institutes, and hospitals |
| Study Period | 2021–2035 |
| Base Year | 2025 |
| Historical Data | 2021–2024 |
| Forecast Period | 2026–2035 |
| Market Size in 2025 | USD 40.10 Billion |
| Market Size in 2035 | USD 61.25 Billion |
| CAGR (2026–2035) | 4.35% |
| Fastest Growing Segments | Life-Science & Genomic Research (6.6% CAGR); Freezers (5.8% CAGR); Hospitals & Diagnostic Centres (5.3% CAGR); Alarm & Monitoring Systems (5.2% CAGR) |
| Regions Covered | North America, Europe, South America, Asia Pacific, Middle East and Africa and ROW |
| Companies Profiled | Thermo Fisher Scientific, PHC Holdings Corporation, Haier Biomedical, Azenta Life Sciences, Eppendorf SE, Merck KGaA, Hamilton Company, Cryoport, Avantor, Liconic AG |
| Valuation Currency | USD Billion |
| Methodology | 350+ primary expert interviews; bottom-up market sizing; top-down validation; data triangulation; scenario-based forecasting; real-time project tracking |

## Frequently Asked Questions

**Q: Should buyers choose mechanical −150 °C freezers or LN2 vapor-phase systems in the biobank equipment market?**
A: Mechanical −150 °C freezers remove dependence on nitrogen supply and the risk of oxygen depletion, but they need continuous power. LN2 vapor-phase tanks hold temperature through outages [8]. Sites with unreliable grids usually choose LN2.

**Q: What accreditation support should procurement teams verify before purchasing storage equipment?**
A: Confirm that equipment and software support ISO 20387:2018 accreditation and 21 CFR Part 11 audit trails [7][11]. Request complete IQ/OQ/PQ validation packages, because requalifying an undocumented unit can delay sample intake by weeks.

**Q: How will the EU SoHO Regulation affect purchasing in the European biobank equipment market?**
A: In Europe, the biobank equipment market will see compliance-driven upgrades before the regulation applies in 2027 [6]. Establishments must document storage conditions and vigilance, which favors freezers with continuous logging and validated alarms.

**Q: Is leasing storage equipment a viable alternative to capital purchase?**
A: Leasing and managed-storage contracts move spending from capital to operating budgets and usually include maintenance and monitoring [21]. They suit hospitals and early-stage biotech firms with uncertain sample volumes, though five-year costs typically exceed outright purchase.

**Q: What service life should buyers plan for a −80 °C freezer?**
A: Most −80 °C freezers deliver 10 to 15 years of service, though hold-over time and compressor efficiency decline in later years [19]. Planning replacements around energy audits avoids emergency purchases after a failure.

**Q: How do natural refrigerants change product selection in the biobank equipment market?**
A: Hydrocarbon refrigerants such as R-290 and R-170 cut global warming potential by more than 99% compared with legacy HFC blends [4]. Buyers should confirm that local fire codes accept flammable refrigerant charges in shared laboratories.

**Q: What integration challenges arise when connecting monitoring systems to existing laboratory software?**
A: Older freezers often lack open APIs, so sites must add external probes and gateways. Mapping each device to inventory records requires validated interfaces and an IT security review under Part 11 [11].


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/biobank-equipment-market-42291*
